Podcast Index
Browse podcasts by category, open recent episodes, and download audio to listen offline.
The BioCentury Show
BioCentury
Telecom Reseller / Technology Reseller News
Telecom Reseller
MoneywebNOW
Moneyweb Radio
EconomX Podcast
economx.hu
L’Edito de Raphael Legendre
BFM Business
The Quarter Hour: the best daily radio industry podcast
podtential originals
Noticias Marketing
Borja Girón
Survive: Essentials for C-Store Assistant Managers
C-Store Center
Thrive: Leadership Skills for C-Store Managers
C-Store Center
Drive: Multi-Unit Excellence for C-Store District Managers
C-Store Center
Arrive: Strategy for Independent C-Store Owners
C-Store Center
CFO Podcast
Peter De Roeck
Les Classiques de l'économie
Radio Classique
Renta 4 Pódcast
Renta 4
Software Defined Talk
Software Defined Talk LLC
The Kings Code Podcast
Tate
Bloomberg News Now
Samejo
Wade Keller Pro Wrestling Post-shows
Pro Wrestling Torch
La Primera de Expansión
Expansión
Black Box - La scatola nera della finanza
Guido Brera e Gian Luca Comandini - Chora Media
Face à Lechypre
BFM Business
L'angle éco de François Lenglet
RTL
Tina Huang
Tina Huang
Alex Becker Channel
Alex Becker Channel
Vacation Rental Revolution Podcast: Building Lifestyle & Financial Freedom With Short-Term Rentals
Shawn Moore
The $100 MBA Show
Omar Zenhom
Leaders Worth Knowing Podcast
Leaders
Scale Her Up: Female business stories and expert tips for business growth and success
Brenda Hector
Market Updates
Marcus Today
Unconventional Knowledge by GIS
Geopolitical Intelligence Services (GIS)
The Adventure Paradox
Cat Caldwell Myers
No Bollocks with Matt Haycox
Matt Haycox
Property Developer Show - The Podcast
Property Developer Show
The Stoic Edge for Managers
Mark Williams
No Trade Secrets
Jarome McKenzie
TraDetector Cafè - Educazione Finanziaria
TraDetector Media
A Morning Message To Start Your Day with Michael Allosso!
Michael Allosso
Business
BioCentury
Roivant CEO Matt Gline calls the company’s move beyond spinning out subsidiary “vants” to concentrating on late-stage programs and commercial launches less a pivot than an evolution toward an original goal, which could s...
Launched in the 1970s as a generics company, Hengrui has become China’s leading innovator in R&D and dealmaking, with more than 100 NMEs in the pipeline and broad alliances with GSK and BMS. Under the leadership of Frank...
Chris Arendt, CSO of Takeda, likens the AI overhaul at the pharma to gutting and rebuilding an old house, from the plumbing and electrical up, while you’re still living there. In a Fireside Chat at Grand Rounds U.S. in S...
ALS drug development has long been hampered by heterogeneity, but Angela Genge — neurologist at McGill University and CMO of AL-S Pharma — argues the field is getting closer to making that heterogeneity tractable. On The...
Richard Pops has lived the biotech roller coaster over three decades as CEO of Alkermes: an IPO, M&A, near-death events for his company, FDA setbacks, battles with an activist investor, and the satisfaction of knowing th...
Karen Knudsen, CEO of the Parker Institute for Cancer Immunotherapy, believes the central problem in cancer drug development is not discovery, but a broken “translational middle.”In a wide-ranging interview on The BioCen...
A paradigm shift in research tools, combined with large-scale unbiased screening, has positioned the biopharma industry not only to rethink target discovery, but also to execute more faithfully on causal biology, accordi...
The European biotech ecosystem has gone through a substantial maturation process over the past 20 years, as VC funds such as Forbion have experienced exponential growth to fund the region’s innovation. But Forbion co-fou...
The U.K. is excellent at invention and science, and creating institutions to further innovation, but poor at capturing their economic value, says Daniel Mahony, a problem that various forces in the U.K. are now putting s...
As AI spreads across biopharma, what will matter most is not who has the flashiest tools, but who can use them to make better medicines. In this episode of The BioCentury Show, Recursion CEO Najat Khan discusses where AI...
There is a real opportunity for artificial intelligence to dramatically transform the speed, cost and efficiency of drug development over the long term, but the uptake of AI tools across biopharma has been much slower re...
Caution: This episode of The BioCentury Show contains strong language.In a candid interview with BioCentury, RA Capital Managing Partner Peter Kolchinsky warns that staffing losses and growing conservatism at FDA are slo...
With disease biology still murky and trials notoriously noisy, psychiatry R&D is advancing fastest where teams can solve engineering problems. Delivery, selectivity and tolerability fixes are turning long-standing hypoth...
Why does great science so often stall before it becomes a medicine? Astellas Pharma CEO Naoki Okamura argues the bottleneck isn’t capital — it’s translation: a shortage of people, processes and platforms that can move id...
Private equity’s expanding role in biopharma as a growth equity investor reflects both the maturation of the life sciences sector and the rising need for large-scale capital, alongside PE firms’ increasing ability to con...
In historical terms, this is not a bear market, says Stelios Papadopoulos. There’s volatility, which is unnerving, and major issues to reckon with, but the level of anxiety in biotech doesn’t reflect the “extraordinary s...
When Bill Hinshaw looks back across the arc of his career — from his early days helping to commercialize Gleevec to his present role leading Fore Biotherapeutics — he sees a precision oncology field transformed by techno...
This is a previously recorded episode of The BioCentury Show from September 5, 2025. Subscribe to this channel to listen to each new episode. Visit TheBioCenturyYouTube.com to access and watch all prior episodes.If you c...
Elias Zerhouni personifies the American dream. He arrived in the U.S. from Algeria as a young man with a couple of hundred dollars in his pocket. Talent, ambition and hard work propelled him into a successful academic ca...
It took Sophie Kornowski under four years as CEO of Boston Pharma to bring it from a pipeline full of in-licensed assets to an acquisition by GSK for about $2 billion in total deal value for a single MASH program. Though...
Fill in the form below. Make sure to select both Country and Genres.
Send us a message below. We will get back to you within 24 hours.